Transthoracic Echocardiography Test

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 MutationLocally Advanced Uterine Corpus LeiomyosarcomaMetastatic Uterine Corpus LeiomyosarcomaPlasma Cell LeukemiaSecondary Acute Myeloid LeukemiaStage III Uterine Corpus Leiomyosarcoma AJCC v8

Phase 1

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

RecruitingNCT05886049

National Cancer Institute (NCI)Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation +1

Start: 2024-06-20End: 2027-12-31Target: 38Updated: 2026-07-16

Phase 2

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruitingNCT05432791

National Cancer Institute (NCI)Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 +2

Start: 2023-03-30End: 2027-01-30Updated: 2026-06-01

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Not yet recruitingNCT07605416

National Cancer Institute (NCI)Plasma Cell Leukemia

Start: 2026-07-29End: 2032-11-06Target: 74Updated: 2026-07-06

Related Papers

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Blood2025-11-03

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.

Journal of Clinical Oncology2025-05-283 citations